Jeff Galvin, CEO of Addimmune, sits down with David Weisburd to discuss cell and gene therapy, and how Addimmune is working on a functional solution for HIV.

We’re proudly sponsored by Bidav Insurance Group, visit lux-str.com if you’re ready to level up your insurance plans.

(0:00) Initial phase 1 results for HIV treatment and blood markers (2:09) Introduction to Jeff Galvin, CEO of Adimmune (2:21) Jeff Galvin's background and transition to gene therapy (8:06) Understanding gene therapy and its potential (11:53) Sponsor: Bidav Insurance Group (12:42) Discussing real successes in gene and cell therapy (16:11) The mechanism of HIV spread and immune system impact (20:13) AGT 103's development for curing AIDS (23:26) Safety and efficacy signals in gene therapy phase one (25:52) Comprehensive phase one study results and future plans (28:47) HIV treatment market from a financial perspective (30:20) The gene and cell therapy revolution (31:45) 10X Capital's public listing and recruitment strategies (34:04) Closing remarks and call to action